Combined liver-kidney transplantation with preformed anti-HLA donor-specific antibodies

Abstract Introduction the impact of preformed donor-specific anti-HLA antibodies (pDSA) after combined liver-kidney transplantation (CLKT) is still uncertain. Method we conducted a retrospective study in 8 European high-volume transplant centers, and investigated the outcome of 166 consecutive CLKT, including 46 patients with pDSA. Results patients’ survival was lower in those with pDSAs (5 years patient survival respectively 63% and 78% with or without pDSA, p= 0.04). The presence of pDSA with a MFI ≥5,000 (HR: 4.96, 95% CI[2.3-10.9], p Conclusion our results suggest that CLKT with pDSA is associated with a lower patients’ survival despite good recipients’, liver and kidney grafts’ outcome.